Zhuolin Zhou

Zhuolin Zhou

Auto-generated profile, based on publicly available information

Zhuolin Zhou

Department of Pharmacy, China Pharmaceutical University, Nanjing Drum Tower Hospital, Nanjing, 211198, China, nju.edu.cn

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ZZZhuolin Zhou
Zhuolin Zhou
NGNan Gao
Nan Gao
JLJiaojiao Liu
Jiaojiao Liu
XMXuerong Ma
Xuerong Ma
ZGZhijuan Ge
Zhijuan Ge
CJCheng Ji
Cheng Ji
Aim: Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and are at greater risk of liver‐related adverse events. Existing non‐invasive tools show limited diagnostic performance in this population. This study aims to develop a predictive model that accurately identifies the risk of MASLD among T2DM patients. Materials and methods: Clinical data were collected from T2DM patients hospitalised at Nanjing Drum Tower Hospital between January 2018 and May 2025. Eight machine learning methods were developed to predict the risk of MASLD in T2DM patients. The discriminatory ability of the models was evaluated using area under the receiver operating characteristic curve (AUROC), area under the precision‐recall curve (AUPRC), accuracy, recall, negative predictive value, positive predictive value, and F1 score. Calibration curves and decision analysis curves were employed to evaluate the calibration and clinical utility. The models were interpreted using the Shapley additive explanations method, and unsupervised clustering was performed to identify potential high‐risk subgroups. Results: A total of 3836 T2DM patients constituted the complete dataset, with a MASLD incidence rate of 55.9%. Thirteen feature variables were selected for model construction, and the XGB model achieved optimal overall performance, with an AUROC of 0.873 and an AUPRC of 0.904. Unsupervised clustering identified several high‐risk subgroups with distinct metabolic characteristics. Conclusion: The model developed enables reliable and interpretable MASLD risk prediction in T2DM patients based on selected commonly available clinical data, providing a practical tool for routine identification and stratified management.

1 January 2026 in International Journal of Endocrinology
Verified
Journal Article
Open access
ZLZixuan Liu
Zixuan Liu
ZZZhuolin Zhou
Zhuolin Zhou
YSYu Sun
Yu Sun
XDXiaotian Du
Xiaotian Du
HZHaixia Zhang
Haixia Zhang
CJCheng Ji
Cheng Ji
Background: Type 2 diabetes mellitus (T2DM) is associated with kidney damage, with microalbuminuria (MAU) serving as an early marker indicating the risk of progression to severe renal and cardiovascular complications, and there is an urgent need for effective prediction tools to identify MAU risk in T2DM patients and prevent adverse outcomes. This study aims to develop a machine learning–based model to enhance the early identification of high‐risk individuals and facilitate timely, personalized interventions. Methods: The electronic medical records of 4170 patients were retrospectively extracted from the diabetes special database of Nanjing Drum Tower Hospital (Ethics approval number: 2021‐403‐02). The data were divided into training and testing sets (8:2 ratio), and random forest–based recursive feature elimination method was employed to identify the most pertinent input variables for the predictive model. Five machine learning models were applied to predict the progression to MAU. The Shapley additive explanations (SHAP) values were applied for model interpretation to assess feature contributions. Ten features were selected for the construction of a prediction model. Results: For predicting the progression to MAU, the Light GBM model demonstrated the best performance (AUC 0.85, 95% CI 0.82–0.88). By analyzing the Shapley values of the model outputs, we identified the key risk factors for predicting the diagnosis of MAU at both the cohort and individual levels. Conclusions: This study developed an interpretable machine learning model to predict MAU in T2DM patients, enabling effective risk stratification and identification of high‐risk individuals based on baseline data to guide personalized clinical interventions and optimization of treatment.